PRV-3279-2a Trial in Systemic Lupus

This was a randomized, double-blind, placebo-controlled study in adult participants with active SLE. Approximately 100 eligible participants were randomized at a 1:1 ratio to receive treatment with either PRV-3279 or placebo. Eligible participants included male or female adults, 18 to 70 years of age, with a diagnosis of SLE for at least 6 months. The study drug was administered every 4 weeks for 20 weeks in a double-blind fashion, followed by an 8-week safety follow-up period.